First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer (Lung-TRIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01038037
Recruitment Status : Terminated (
  1. Very low enrollment rate.
  2. Recent studies question the effect of adding panitumumab in this category of patients.
  3. Too high toxicity rate
First Posted : December 23, 2009
Last Update Posted : December 4, 2014
Information provided by (Responsible Party):
Vejle Hospital

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : June 2013
  Actual Study Completion Date : December 2013